Pathologists are integral to ongoing patient management by monitoring treatment response. They track the variant allele frequency of KIT D816V in blood and assess mast cell reduction in follow-up biopsies to determine if therapies like TKIs are effective or if the disease is worsening, extending their role far beyond initial diagnosis.
Recent drug approvals for non-advanced systemic mastocytosis were based on patient-reported outcomes (PROs) measuring symptom improvement. While biomarkers like serum tryptase often correlate, the primary measure of success is the patient's subjective experience. This presents a challenge for monitoring effectiveness in routine clinical practice outside of formal trials.
The high efficacy of new drugs for systemic mastocytosis is prompting consideration of "drug holidays." This would allow patients, who have a near-normal life expectancy, to temporarily stop treatment for major life events like planning a family. This signals a paradigm shift from continuous therapy to intermittent disease management for chronic conditions.
For non-advanced systemic mastocytosis, new drugs are differentiated by their side effect profiles, not just efficacy. Avapritinib can cause cognitive effects as it crosses the blood-brain barrier, while bezuclastinib may cause transient liver enzyme elevation. This allows for personalized treatment choices based on patient tolerability and lifestyle.
While new therapies effectively control daily symptoms in non-advanced systemic mastocytosis, significant unmet needs remain. The next generation of treatments must demonstrate an ability to reduce the risk of severe complications like life-threatening anaphylaxis and debilitating fragility fractures, which current pivotal trials were not powered to properly assess.